BioSyent Inc.
RX.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -10.31% | 7.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -10.31% | 7.18% | |||
| Cost of Revenue | -22.71% | 10.82% | |||
| Gross Profit | -6.88% | 6.22% | |||
| SG&A Expenses | 102.31% | -7.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 87.83% | -2.46% | |||
| Operating Income | 58.29% | 42.33% | |||
| Income Before Tax | -26.28% | 38.82% | |||
| Income Tax Expenses | -6.87% | 17.48% | |||
| Earnings from Continuing Operations | -31.90% | 46.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.90% | 46.51% | |||
| EBIT | 58.29% | 42.33% | |||
| EBITDA | 72.62% | 40.34% | |||
| EPS Basic | -31.37% | 46.59% | |||
| Normalized Basic EPS | 62.70% | 38.96% | |||
| EPS Diluted | -31.12% | 46.07% | |||
| Normalized Diluted EPS | 63.05% | 38.42% | |||
| Average Basic Shares Outstanding | -0.79% | -0.06% | |||
| Average Diluted Shares Outstanding | -0.90% | 0.20% | |||
| Dividend Per Share | -2.73% | 0.30% | |||
| Payout Ratio | 0.41% | -0.32% | |||